New review examines potential of medicinal cannabis to help treat intractable epilepsy

A new British Journal of Clinical Pharmacology review examines the potential of medicinal cannabis--or medical marijuana--for helping patients with intractable epilepsy, in which seizures fail to come under control with standard anticonvulsant treatment.

The authors note that cannabidiol--the most researched compound of cannabis--may have modest efficacy and be appropriate for children with severe epilepsy, but attention must be paid to potential side effects and drug interactions. There is no evidence to guide physicians in ranking cannabidiol among current antiepileptic drugs, and it will be important to continue studying its potential through rigorous clinical trials.

"The emergence over the past 12 months of the first successful double-blind randomized controlled trials of cannabidiol is good news for some desperate families of children with severe epilepsy. These studies are a reminder though that this drug is no miracle, and we still have much to learn," said co-author Dr. John Anthony Lawson, of Sydney Children's Hospital, Randwick, in Australia.

Source: https://newsroom.wiley.com/press-release/british-journal-clinical-pharmacology/can-medical-marijuana-help-treat-intractable-epi

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17